Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A

GENEVA–(BUSINESS WIRE)–STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) – including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay – today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M).

The round was supported by a consortium of Swiss, European and US private equity and Biotech experienced investors. STALICLA will use the proceeds of this second tranche to move its lead ASD precision medicine candidate – STP1 – into Phase 1b clinical trials and its second program, STP2, into IND enabling pre-clinical studies.
Funds will also support the scale-up of STALICLA’s first in class Neurodevelopmental Disorder focused discovery platform. This new round of financing brings the company’s total equity financing to USD 18.4M over the last 30 months.